Atara Biotherapeutics Inc (ATRA) to Post Q1 2018 Earnings of ($0.89) Per Share, William Blair Forecasts

Atara Biotherapeutics Inc (NASDAQ:ATRA) – Equities research analysts at William Blair boosted their Q1 2018 earnings estimates for shares of Atara Biotherapeutics in a report issued on Tuesday. William Blair analyst M. Phipps now anticipates that the biotechnology company will earn ($0.89) per share for the quarter, up from their previous estimate of ($1.08). William Blair also issued estimates for Atara Biotherapeutics’ Q2 2018 earnings at ($0.88) EPS, Q3 2018 earnings at ($0.90) EPS, Q4 2018 earnings at ($0.92) EPS, FY2018 earnings at ($3.59) EPS, FY2019 earnings at ($4.00) EPS, FY2020 earnings at ($3.06) EPS and FY2021 earnings at ($2.20) EPS.

Several other research analysts have also recently issued reports on ATRA. Canaccord Genuity restated a “buy” rating on shares of Atara Biotherapeutics in a report on Thursday, November 9th. ValuEngine upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Friday, December 29th. Citigroup upgraded shares of Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 target price for the company in a report on Wednesday, January 3rd. BidaskClub upgraded shares of Atara Biotherapeutics from a “hold” rating to a “buy” rating in a report on Thursday, January 11th. Finally, Cowen initiated coverage on shares of Atara Biotherapeutics in a research note on Friday, January 26th. They set an “outperform” rating for the company. Two analysts have rated the stock with a sell rating, two have issued a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $30.60.

Atara Biotherapeutics (NASDAQ ATRA) opened at $48.35 on Thursday. Atara Biotherapeutics has a twelve month low of $11.80 and a twelve month high of $49.90. The stock has a market cap of $1,693.69, a price-to-earnings ratio of -13.93 and a beta of 2.71.

In related news, EVP Heather D. Turner sold 12,214 shares of the stock in a transaction on Friday, February 9th. The shares were sold at an average price of $38.01, for a total transaction of $464,254.14. Following the completion of the sale, the executive vice president now owns 77,112 shares in the company, valued at approximately $2,931,027.12. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Gad Soffer sold 7,000 shares of the stock in a transaction on Friday, November 17th. The stock was sold at an average price of $15.00, for a total transaction of $105,000.00. Following the sale, the executive vice president now owns 166,342 shares of the company’s stock, valued at approximately $2,495,130. The disclosure for this sale can be found here. In the last quarter, insiders have sold 297,914 shares of company stock valued at $8,074,587. 16.20% of the stock is owned by company insiders.

Institutional investors have recently made changes to their positions in the business. Pacific Heights Asset Management LLC purchased a new position in Atara Biotherapeutics during the 4th quarter worth $453,000. Schwab Charles Investment Management Inc. raised its position in Atara Biotherapeutics by 16.8% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 92,974 shares of the biotechnology company’s stock worth $1,302,000 after buying an additional 13,394 shares during the last quarter. Perceptive Advisors LLC purchased a new position in Atara Biotherapeutics during the 3rd quarter worth $581,000. Essex Investment Management Co. LLC purchased a new position in Atara Biotherapeutics during the 3rd quarter worth $429,000. Finally, Vanguard Group Inc. raised its position in Atara Biotherapeutics by 1.7% during the 2nd quarter. Vanguard Group Inc. now owns 845,877 shares of the biotechnology company’s stock worth $11,842,000 after buying an additional 13,952 shares during the last quarter. Institutional investors own 69.58% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/15/atara-biotherapeutics-inc-atra-to-post-q1-2018-earnings-of-0-89-per-share-william-blair-forecasts.html.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply